Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The sialyl-Tn (sTn) antigen is a well known
cancer-associated
antigen, the expression of which is related to the prognosis of cancer patients. We aimed to isolate a human gene encoding an N -acetylgalactosamine alpha2,6-sialyltransferase which synthesizes sTn antigen, and to characterize the enzyme. Degenerate primers encoding sialyl motifs were used for the polymerase chain reaction to amplify complementary DNAs prepared from RNAs of human pyloric mucosae with intestinal metaplasia, which abundantly expressed sTn antigen, followed by screening of full-length cDNAs using the amplified DNA fragment as a probe. We isolated two human cDNA clones, long-form (2.46 kb) and short-form (2.23 kb) cDNAs. The former encodes an active enzyme with a predicted 600 amino acid sequence. The latter, a splice-variant of the long-form, encodes an inactive enzyme. HCT15 human colorectal cancer cells stably expressing the long-form cDNA expressed sTn epitopes on O -glycans. The long form cDNA was considered to encode a human homologue of chick
ST6GalNAc I
for the following reasons: (1) the putative amino acid sequence showed greater homology to that of chick
ST6GalNAc I
(55%) compared to other sialyltransferases, (2) it encodes the extraordinarily long stem region that is a typical feature of chick
ST6GalNAc I
, and (3) the substrate specificity was very similar to that of chick
ST6GalNAc I
. In situ hybridization demonstrated that the localization of transcripts correlated well with that of sTn antigen in gastric cancer cells and Goblet cells in intestinal metaplastic glands. Thus, we determined that the long-form cDNA of the human
ST6GalNAc I
gene encodes the probable candidate for the human sTn synthase(s).
...
PMID:Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. 1053 37
Sialyl-Tn antigen (STn) is a
cancer associated
carbohydrate antigen over-expressed in several cancers including breast cancer, and currently associated with more aggressive diseases and poor prognosis. However, the commonly used breast cancer cell lines (MDA-MB-231, T47-D and MCF7) do not express STn antigen. The key step in the biosynthesis of STn is the transfer of a sialic acid residue in alpha2,6-linkage to GalNAc alpha-O-Ser/Thr. This reaction is mainly catalyzed by a CMP-Neu5Ac GalNAc alpha2,6-sialyltransferase:
ST6GalNAc I
. In order to generate STn-positive breast cancer cells, we have cloned a cDNA encoding the full-length human
ST6GalNAc I
from HT-29-MTX cells. The stable transfection of MDA-MB-231 with an expression vector encoding
ST6GalNAc I
induces the expression of STn antigen at the cell surface. The expression of STn short cuts the initial O-glycosylation pattern of these cell lines, by competing with the Core-1 beta1,3-galactosyltransferase, the first enzyme involved in the elongation of O-glycan chains. Moreover, we show that STn expression is associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.
...
PMID:Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. 1282 Jul 22
Sialyl-Tn is a simple mucin-type carbohydrate antigen aberrantly expressed in gastrointestinal adenocarcinomas and in the precursor lesion intestinal metaplasia. Sialyl-Tn tumour expression is an independent indicator of poor prognosis. We have previously shown in vitro that
ST6GalNAc-I
and ST6GalNAc-II sialyltransferases can synthesize sialyl-Tn. The aim of the present study was to establish whether
ST6GalNAc-I
is the major enzyme responsible for the expression of sialyl-Tn. We used a model of CHO-ldlD cells producing only MUC1-Tn glycoform and showed that
ST6GalNAc-I
is the key-enzyme leading to sialyl-Tn biosynthesis. We developed novel monoclonal antibodies specific for
ST6GalNAc-I
and evaluated its expression in gastrointestinal tissues.
ST6GalNAc-I
was detected in normal colon mucosa co-localized with O-acetylated sialyl-Tn. Expression was largely unaltered in colorectal adenocarcinomas. In contrast, we found that
ST6GalNAc-I
is weakly expressed in normal gastric mucosa, but over-expressed in intestinal metaplasia, co-localized with sialyl-Tn. In gastric carcinomas
ST6GalNAc-I
was also associated with sialyl-Tn, but with heterogeneous staining and partial co-localization. Our results showed
ST6GalNAc-I
as the major enzyme controlling the expression of
cancer-associated
sialyl-Tn antigen in gastrointestinal tissues.
...
PMID:ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. 2162 48